317 related articles for article (PubMed ID: 16426593)
1. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
Jacqueminet S; Ben Abdesselam O; Chapman MJ; Nicolay N; Foglietti MJ; Grimaldi A; Beaudeux JL
Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
3. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
4. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
[TBL] [Abstract][Full Text] [Related]
6. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
9. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.
El Messal M; Beaudeux JL; Drissi A; Giral P; Chater R; Bruckert E; Adlouni A; Chapman MJ
Clin Chim Acta; 2006 Apr; 366(1-2):185-9. PubMed ID: 16280123
[TBL] [Abstract][Full Text] [Related]
11. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes.
Kadoglou NP; Vrabas IS; Sailer N; Kapelouzou A; Fotiadis G; Noussios G; Karayannacos PE; Angelopoulou N
Diabetes Metab; 2010 Apr; 36(2):144-51. PubMed ID: 20149706
[TBL] [Abstract][Full Text] [Related]
12. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
13. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
14. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
15. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
16. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
[TBL] [Abstract][Full Text] [Related]
17. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes.
Xue M; Thompson PJ; Clifton-Bligh R; Fulcher G; Gallery ED; Jackson C
Int J Biochem Cell Biol; 2005 Nov; 37(11):2406-16. PubMed ID: 16054858
[TBL] [Abstract][Full Text] [Related]
19. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
20. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
